sPD-L1 levels increased during the first weeks but correlated differently depending on the so-called “immunogenic” tumor type: while in NSCLC patients, an increase of >100% in sPD-L1 levels during the first weeks of ICI treatment was significantly associated with better outcomes (both PFS and OS), in melanoma patients, the same increase in sPD-L1 levels after initiating treatment showed a reverse relationship with worse PFS outcomes (0.9 vs. 5.7 months) [19]. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.